The following study has recently been activated for patient enrollment by the University of Illinois Cancer Center Clinical Trials Office (CTO). Please click on the link to learn about the details regarding the study on clinicaltrials.gov. For more information or questions about the study, please email [email protected] or call 312-355-5112.
A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects with Non-Small Cell Lung Cancer with High PD-L1 Expression
Sponsor: BrightPath Biotherapeutics
Principal Investigator: Lawrence Feldman, MD